Singapore: WuXi PharmaTech's Laboratory Testing Division (LTD) has partnered with Lee Pharma as an exclusive supplier of laboratory testing services for portfolio of discovery and IND/NDA package services, including chemistry analytical services, in vitro and in vivo biology, oncology, immunology, in vitro ADME, pharmacokinetic / pharmacodynamic studies, toxicology, and clinical bioanalysis.

LTD will provide dedicated program management, streamline project coordination across WuXi, and allocate the necessary resources and R&D development efforts for Lee's Pharma programs.

"We are delighted to become exclusive supplier of the broad range of laboratory testing services for the drug discovery portfolio of Lee's Pharm," said Dr Ge Li, chairman and CEO, WuXi PharmaTech. "WuXi has been building a comprehensive and integrated R&D enabling platform, and this strategic collaboration is an example of delivering that platform to serve our innovative partners."

"WuXi's impressive platform of lab testing services will allow our compounds to advance seamlessly through discovery, preclinical, and clinical development," commented Dr Benjamin Li, executive director and CEO, Lee's Pharma. "We are confident that this strategic partnership with LTD will streamline and accelerate our drug discovery program."